CIHR Commercialization Program funds insulin-alternative stem cell technology and nicotine addiction drug therapy
TORONTO (March 2, 2010) – MaRS Innovation is delighted to announce that two of its commercialization projects – notably an umbilical cord stem cell technology from Mount Sinai Hospital and nicotine…